Related Experiment Videos

[Juvenile malignant lymphomas. 2 Non-Hodgkin lymphomas]

Folia Haematologica (Leipzig, Germany : 1928)
|January 1, 1981
PubMed

Insights

This study on pediatric Non-Hodgkin lymphomas (NHL) found that advanced stages (III-IV) and specific types like Burkitt-type had lower remission rates. Early stages and unclassified lymphoblastic NHL showed better outcomes.

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Immunology

Context:

  • Non-Hodgkin lymphomas (NHL) in children present diagnostic and therapeutic challenges.
  • Treatment outcomes vary significantly based on disease stage and histological subtype.
  • Understanding surface markers aids in classifying and predicting NHL behavior.

Purpose:

  • To analyze treatment outcomes for pediatric Non-Hodgkin lymphomas (NHL) based on histological classification and disease stage.
  • To correlate histological subtypes (e.g., Burkitt-type, convoluted cell) and Ann Arbor staging with remission rates.
  • To evaluate the effectiveness of combined therapy including irradiation, chemotherapy, and surgery.

Summary:

  • A cohort of 33 children (ages 2-15) with NHL were treated between 1970-1978.
  • Histological classification (Kiel) and surface markers were assessed alongside Ann Arbor staging.
  • Therapies included irradiation, chemotherapy, and surgery; 3-year remission rates were 50% for stages I-II and 20% for stages III-IV.

Impact:

  • Early-stage pediatric NHL and unclassified lymphoblastic subtypes demonstrated better 3-year remission rates (42%) compared to advanced stages.
  • Convoluted cell and Burkitt-type NHL showed poorer prognoses with lower remission rates (16% and 27%, respectively).
  • Findings highlight the importance of histological subtype and stage in predicting treatment response for childhood NHL.

Related Concept Videos